Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension-Reference-Cited by-同舟云学术

Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

Published:2014-08-20 Issue:9 Volume:29 Page:2051-2056
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Brown Jacques P¹,Reid Ian R²,Wagman Rachel B³,Kendler David⁴,Miller Paul D⁵,Jensen Jens-Erik Beck⁶,Bolognese Michael A⁷,Daizadeh Nadia³,Valter Ivo⁸,Zerbini Cristiano AF⁹,Dempster David W¹⁰¹¹

Affiliation:

1. Laval University and CHU de Québec-(CHUL) Research Centre; Quebec City Canada

2. University of Auckland; Auckland New Zealand

3. Amgen Inc.; Thousand Oaks CA USA

4. University of British Columbia; Vancouver Canada

5. Colorado Center for Bone Research; Lakewood CO USA

6. Hvidovre Hospital; Hvidovre Denmark

7. Bethesda Health Research Center; Bethesda MD USA

8. Center for Clinical and Basic Research; Tallinn Estonia

9. Centro Paulista de Investigação Clinica; São Paulo Brazil

10. Columbia University; New York NY USA

11. Helen Hayes Hospital; West Haverstraw NY USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference27 articles.

1. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo;Lacey;Am J Pathol.,2000

2. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation;Lacey;Cell.,1998

3. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function;Udagawa;Endocrinology.,2000

4. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL;Yasuda;Proc Natl Acad Sci USA.,1998

5. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;N Engl J Med.,2009

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting;International Urology and Nephrology;2024-06-10

2. Drugs associated with medication-related osteonecrosis of the jaw;Handbook of Dental Therapeutics;2024-03-31

3. Clinical Characteristics and Management of Hypercalcemic Crisis in 155 Patients: A Single Center Retrospective Study;International Journal of Endocrinology;2024-01

4. Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease;Metastatic Bone Disease;2024

5. Biologic Antiresorptive: Denosumab;Indian Journal of Orthopaedics;2023-12